A novel melanoma gene (MG50) encoding the interleukin 1 receptor antagonist and six epitopes recognized by human cytolytic T lymphocytes

Cancer Research

Volumn 60, Issue 22, 2000, Pages 6448-6456

  Mitchell, Malcolm S ^a,b   Kan Mitchell, June ^a,b   Minev, Boris ^a,b   Edman, Carl ^a,b   Deans, Robert J ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPITOPE; GENE PRODUCT; HLA A ANTIGEN; HLA A2 ANTIGEN; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; MELANOMA ANTIGEN; MUTANT PROTEIN; PROTEIN MG50; UNCLASSIFIED DRUG;

AMINO ACID SEQUENCE; ANTIGEN RECOGNITION; ARTICLE; BREAST CARCINOMA; CANCER IMMUNOLOGY; COLON CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; GENE SEQUENCE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MELANOMA; OVARY CARCINOMA; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA;

AMINO ACID SEQUENCE; ANTIGENS, NEOPLASM; BASE SEQUENCE; EPITOPES, T-LYMPHOCYTE; HLA-A2 ANTIGEN; HUMANS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; MELANOMA; MOLECULAR SEQUENCE DATA; NEOPLASM PROTEINS; OPEN READING FRAMES; PROTEIN STRUCTURE, SECONDARY; RECEPTORS, INTERLEUKIN-1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SIALOGLYCOPROTEINS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED;

EID: 0033677366     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (41)

1. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma
2. Genes coding for tumor rejection antigens: Perspectives for specific immunotherapy
3. Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor
4. Isolation of cDNA clones encoding T cell-specific membrane-associated protein
5. Novel gene sequences expressed by human melanoma cells identified by molecular subtraction
6. Active specific immunotherapy of melanoma. Phase I trial of allogeneic melanoma lysates and a novel adjuvant
7. Assignment of a human melanoma associated gene MG50 (D2S448) to chromosome 2p25.3 by fluorescence in situ hybridization
8. Differential S100 β expression in choroidal and skin melanomas: Quantitation by the polymerase chain reaction
9. Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction
10. Consensus motifs and peptide ligands of MHC class I molecules
11. Class I MHC-peptide interactions: Structural requirements and functional implications
12. Binding of a peptide antigen to multiple HLA alleles allows definition of an A2-like supertype
13. Induction of tumor-reactive CTL from peripheral blood and tumor- infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1
14. Transfected Drosophila cells as a probe for defining the minimal requirements for stimulating unprimed CD8+ T cells
15. Biomagnetic isolation of antigen-specific CD8+ T cells usable in immunotherapy
16. Peroxidasin: A novel enzyme matrix protein of Drosophila development
17. GOR method for predicting protein secondary structure from amino acid sequence
18. Amino acid sequences common to rapidly degraded proteins: The PEST hypothesis
19. Melanoma-associated antigens recognized by cytotoxic T lymphocytes
20. Cell biology of antigen processing and presentation to MHC class I molecule-restricted T lymphocytes
21. Peptide binding to the most frequent HLA-A class 1 alleles measured by quantitative molecular binding assays
22. Clonal analysis of in vitro-activated CD8+ cytotoxic T lymphocytes from a melanoma patient responsive to active specific immunotherapy
23. Non-fastidious, melanoma-specific CD8+ cytotoxic T lymphocytes from chomidal melanoma patients
24. A personal (biased) perspective on cancer 'vaccines'
25. Perspective on allogeneic melanoma lysates in active specific immunotherapy
26. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
27. Synthetic insertion signal sequences enhance class I presentation of a peptide from the melanoma antigen MART-1
28. Potentiation of the T-lymphocyte response to mitogens. II. The cellular source of potentiating mediator(s)
29. Potentiation of the T-lymphocyte response to mitogens. I. The responding cell
30. Potentiation of cultured mouse thymocyte responses by factors released by peripheral leucocytes
31. On the mode of action of BCG
32. Stimulation of lymphoid cells by components of BCG
33. Activation of lymphoid cells by BCG in vitro
34. Evaluation of interleukin-1 receptor antagonist (IL-1RA) and tumor necrosis factor binding protein (TNF-BP) in a rodent abscess model of host resistance
35. Increased circulating cytokines, cytokine antagonists, and E-selectin after intravenous administration of endotoxin in humans
36. Secretory interleukin-1 receptor antagonist gene expression requires both a PU.1 and a novel composite NF-κB/PU.1/GA-binding protein binding site
37. Interleukin-18 (IFN-γ-inducing factor) induces IL-8 and IL-1β via TNFα production from non-CD14+ human blood mononuclear cells
38. Interleukin-1 receptor antagonist decreases bone loss and bone resorption in ovariectomized rats
39. Host-tumor interaction in ovarian cancer. Spontaneous release of tumor necrosis factor and interleukin-1 inhibitors by purified cell populations from human ovarian carcinoma in vitro